Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Beginnen de maand op 9 en eindigen op 10,50 naar mijn verwachting. Sentiment slaat wel om verkiezingen uit de weg en shorters hebben hun buit ook wel weer binnen.
Dat is mijn verwachting ook. Eind december tussen de 11.50 en 12.00 Onmaneus ik zal maar snel instappen als ik u was. Groet PM
Longterm Lijkt er op dat we een goede prognose hebben. Nu de 10, 11 etc nog. Groet PM
Onder de negen; nu bepalen of ik nog even wacht of instap.
Aandeeltje, Mooi instapmoment. Denk dat dit aandeel niet veel verder zal dalen. Volgens Tostram beperkt neerwaarts risico en hoog stijgingspotentieel. Zelf heb ik gekocht op 10,015 en 9.54. Groet PM
Kan elk moment erg snel gaan. Niemand nog die de bied wil leveren. PM
Ik verwacht dat er toch eerst eens nieuws moet komen wat er in USA is besproken voordat we weer wat rust in het aandeel krijgen. Tot nu toe dalen we alleen maar. Voor je het weet staan we bij de steun als we zo doorgaan.
De Belgische FSMA heeft voor de 2e dag op rij de shortposities niet bijgewerkt. De laatste stand is van afgelopen donderdag met 1,79% oftewel ca. 1,3 miljoen aandelen, verdeeld over 3 partijen. (0,5% - 0,6% - 0,69%).
Er hangen claims boven dit aandeel uit USA de koers gaat terg naar de 4.50 op basis van lucht en oppompen omhoog kijk naar Ordina zelfde verhaal boemm 16% eraf dit aandeel gaat de zelfde kant op Tostrams geeft verkoopsignaal
moneymaker_BX schreef op 1 november 2016 19:22 :
Er hangen claims boven dit aandeel uit USA
de koers gaat terg naar de 4.50
op basis van lucht en oppompen omhoog
kijk naar Ordina zelfde verhaal boemm 16% eraf
dit aandeel gaat de zelfde kant op
Tostrams geeft verkoopsignaal
Is het mogelijk er wen bron bij te vermelden? Ik kan allen dit vinden www.tostrams.nl/artikel-detail.aspx?I... Fagron valt door de steun 8,99 aan de onderkant van het zijwaarts gerichte koerspatroon. Fagron is door verkopers door de voorgaande bodem gedrukt. Hierdoor is een technische verzwakking opgetreden. Een dalende trend wordt gestart richting steun 8,15 (gevormd op 12 september). Enkel boven weerstand 10,59 (gevormd op 11 oktober) klaart het beeld op
moneymaker_BX schreef op 1 november 2016 19:22 :
Er hangen claims boven dit aandeel uit USA
de koers gaat terg naar de 4.50
op basis van lucht en oppompen omhoog
kijk naar Ordina zelfde verhaal boemm 16% eraf
dit aandeel gaat de zelfde kant op
Tostrams geeft verkoopsignaal
Hebben we hem ook weer zeg... eurotje er af nadat we zo'n 6 omhoog zijn gegaan en meneer begint meteen weer heerlijk te bashen. Koersen gaan nooit maar 1 kant op zo ook met Fagron een dipje is niets mis mee.
Fagron stuitert altijd flink, maar er zit al een tijd een mooie lijn in. Dit is tijdelijk. Je zou overigens eens op het Tomtom forum moeten roepen dat de koers naar 3 euro gaat i.v.m. claims en 'lucht'...
Omaneus, Jouw 8 euro is in zicht. Zelf zit ik er vol in met een gemiddelde aankoopprijs van 9.81. Stijgingen en dalingen horen er gewoon bij. Heb er nog steeds alle vertrouwen in dat we eind van het jaar ergens tussen de 11.50 en 12 euro staan. Groet PM
Pfizer : Cuts Outlook, Ends Development of Cholesterol Drug 0 11/01/2016 | 12:56pm CET By Austen Hufford and George Stahl Pfizer Inc. on Tuesday lowered its earnings outlook for the year and said it was ending the development of a drug in the massive cholesterol-treatment sector. Shares of the company fell 2.2% premarket. Pfizer said it ended development of its cholesterol treatment bococizumab because it was losing efficacy over time in lowering so-called bad cholesterol. Bococizumab is part of a class of drugs, known as PCSK9 inhibitors, which aims to reduce levels of low-density lipoprotein cholesterol beyond what can be achieved by an older class of drugs known as statins. Lower levels of LDL is associated with reduced risk of heart attacks and strokes, but it hasn't been proven in trials that this type of drug actually has reduced cardiovascular risk. The company plans to record a charge of 4 cents a share in the fourth quarter because of costs from the program's discontinuation. For the full year, Pfizer said it now expects earnings per share of $2.38 to $2.43, reducing the high-end of the range by 5 cents. It also now expects revenue of between $52 billion to $53 billion, increasing the low end of the revenue forecast by $1 billion. In September, Pfizer said it had decided not to split into two companies after long considering the move. Pfizer spent at least $600 million preparing for a potential split before deciding not to, saying a supposed "valuation gap" between the company's market value and the value of its individual units has closed over time. In the latest quarter, Pfizer reported a profit of $1.32 billion, or 21 cents a share, down from $2.13 billion, or 34 cents a share a year prior. Excluding certain items, adjusted earnings were 61 cents a share, up from 60 cents. Revenue rose 7.9% to $13.05 billion. Analysts polled by Thomson Reuters had forecast adjusted earnings of 62 cents a share on revenue of $13.05 billion. Write to Austen Hufford at austen.hufford@wsj.com and George Stahl at george.stahl@wsj.com
Shire : Cuts Guidance After Posting Third-Quarter Loss share with twitter share with LinkedIn share with facebook share via e-mail 0 11/01/2016 | 02:03pm CET By Denise Roland Shire PLC cut its full-year guidance and reported a net loss in the three months to Sept. 30, both because of heavy spending on the integration of its $32 billion acquisition of Baxalta Inc. Dublin-based Shire said it would post a diluted loss per American Depository Share of between 70 cents and $1.10 in 2016, having previously said it would post between zero earnings per ADS and a 40 cent loss. The company reported a net loss of $387 million for the three months to Sept. 30. Meanwhile, revenue more than doubled to $3.5 billion, from $1.7 billion a year earlier. Analysts expected net profit of $903 million and revenue of $3.6 billion. Non-GAAP operating income, a measure that strips out certain one-time gains and losses, as well as tax and interest, increased 73% to $1.3 billion. Write to Denise Roland at Denise.Roland@wsj.com
Valeant, Saddled With Debt, in Talks to Sell Big Drug Line share with twitter share with LinkedIn share with facebook share via e-mail 0 11/01/2016 | 09:05pm CET Valeant Pharmaceuticals International Inc. is in advanced talks to sell a big stomach-drug business to Japan's Takeda Pharmaceutical Co. for about $10 billion, a move seen easing pressure on Valeant over its hefty debt load. The companies could reach a deal for Salix Pharmaceuticals Ltd., which Valeant bought just a year-and-a-half ago for roughly $11 billion, in the coming weeks, people familiar with the matter said. The purchase price would include about $8.5 billion in cash and future royalty payments to Valeant, the people said. There is no guarantee the companies will reach a deal and, indeed, there is another unnamed potential bidder in the mix, the people said. Valeant confirmed the discussions late Tuesday, saying, "We are currently in discussions with third parties for various divestitures including but not limited to Salix. The discussions may or may not lead to a definitive agreement." Valeant shares jumped after The Wall Street Journal reported on the potential deal, rising 34% to close at $23.86. Should Valeant strike a deal, it would allow the company to largely pay back its bank lenders, removing a big area of concern for investors ever since the drugmaker became embroiled in an accounting scandal last year. Valeant has told investors it would work to reduce its debt load, but the company was expected to do so through a series of smaller steps. It would also likely allow Valeant's new chief executive, Joseph Papa, to focus on rebuilding Valeant's core franchises in skin and eye drugs, which have been struggling. If it sells Salix, Valeant's top-selling products would be an off-patent antidepressant named Wellbutrin and Bausch & Lomb's SofLens daily disposable contact lenses. The company would be expected to double down on its skin and eye drugs, such as some acne treatments and over-the-counter vitamins taken for eye health. Valeant also has high hopes for a psoriasis treatment, brodalumab, that is up for regulatory approval. Salix makes treatments for stomach disorders like traveler's diarrhea and irritable bowel syndrome, or IBS. For Takeda, the purchase would come after it lost out on earlier attempts to buy Salix and deliver big-selling gastrointestinal drugs it has been seeking to bolster its lineup of stomach remedies. At the time of Valeant's Salix deal, the Canadian drug company was riding high on a strategy of acquiring companies and consolidating their research-and-development budgets. But then Valeant's business tactics and accounting came under intense scrutiny, leading to government investigations and the departure of its CEO, Michael Pearson, and other executives. Valeant's highflying stock plunged on fears it wouldn't be able to keep up its prior pace of acquisition-led growth and that its $30 billion of debt was too much. Investors have been particularly focused on the roughly $12 billion Valeant owes banks, given that the vast majority of its $19 billion in public bonds don't start coming due before 2020. Valeant took on roughly half its current debt load to pay for Salix after it won a heated bidding war for the company. Valeant-with a market value of about $8.3 billion at Tuesday's close, after its stock had dropped more than 90% from its highs in 2015-has been working with a number of banks to explore sales of various assets, and these efforts are also progressing, the people said. Valeant preferred to sell other parts of its business, but Salix was viewed as the most attractive asset for rivals, they said. Selling Salix for less than it paid in April 2015 could hand Valeant a loss it could use to offset gains from other asset sales. Takeda swooped in with an offer to start the talks. Takeda, Japan's largest drugmaker by revenue, vied for Salix in the previous auction, and combined on an abortive offer for all of Valeant with private-equity TPG, The Wall Street Journal r eported earlier this year. Salix would give Takeda a drug for IBS called Xifaxan that Valeant had predicted could have $1 billion in sales this year. Sales haven't done as well as some analysts expected, however. Many Salix sales representatives left the company, and Xifaxan has faced fierce competition from a competing drug, Viberzi, from Allergan PLC. Meanwhile, Teva Pharmaceutical Industries Ltd. also is working on a generic version of Xifaxan. Takeda is likely betting that its sales force, which already sells products like a fast-growing ulcerative-colitis drug called Entyvio, could help increase sales of Xifaxan and other Salix products. Like other Japanese drug companies, Takeda is seeking growth in the U.S. and other lucrative markets to offset pressures in its home country. The Japanese company has singled out stomach treatments as a priority. In March, its U.S. unit said it was reorganizing to focus on gastrointestinal disorders, along with a few other conditions. Dana Mattioli Write to David Benoit at david.benoit@wsj.com and Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com
Pharmaceutical : Japan's Takeda shares halted on news of interest in Valeant assets share with twitter share with LinkedIn share with facebook share via e-mail 0 11/02/2016 | 06:39am CET Trading in shares of Japan's Takeda Pharmaceutical Co (>> Takeda Pharmaceutical Co Ltd) was suspended in Tokyo on Wednesday after news the company was interested in buying Canadian drugmaker Valeant Pharmaceuticals International Inc's (>> Valeant Pharmaceuticals Intl Inc) stomach-drug business. Trading in shares of Japan's Takeda Pharmaceutical Co (>> Takeda Pharmaceutical Co Ltd) was suspended in Tokyo on Wednesday after news the company was interested in buying Canadian drugmaker Valeant Pharmaceuticals International Inc's (>> Valeant Pharmaceuticals Intl Inc) stomach-drug business. People familiar with the matter told Reuters the deal for the sale of the Salix business could raise as much as $10 billion for Valeant. A Takeda spokesman said the company had no immediate comment but would release a comment through the stock exchange shortly. (Reporting by Chang-Ran Kim; Editing by Richard Pullin) Stocks treated in this article : Valeant Pharmaceuticals Intl Inc, Takeda Pharmaceutical Co Ltd
Valeant Nears $10 Billion Salix Sale -- WSJ share with twitter share with LinkedIn share with facebook share via e-mail 0 11/02/2016 | 07:49am CET By David Benoit and Jonathan D. Rockoff Valeant Pharmaceuticals International Inc. is in advanced talks to sell a big stomach-drug business to Japan's Takeda Pharmaceutical Co. for about $10 billion, a move seen easing pressure on Valeant over its hefty debt load. The companies could reach a deal for Salix Pharmaceuticals Ltd., which Valeant bought just a year-and-a-half ago for roughly $11 billion, in the coming weeks, people familiar with the matter said. The purchase price would include about $8.5 billion in cash and future royalty payments to Valeant, the people said. There is no guarantee the companies will reach a deal and, indeed, there is another unnamed potential bidder in the mix, the people said. Valeant confirmed the discussions late Tuesday, saying, "We are currently in discussions with third parties for various divestitures including but not limited to Salix. The discussions may or may not lead to a definitive agreement." Valeant shares jumped after The Wall Street Journal reported on the potential deal, rising 34% to close at $23.86. On Wednesday, Takeda said it was in discussions with many parties about potential deals to accelerate growth, but declined to comment directly on the Journal report. Should Valeant strike a deal, it would allow the company to largely pay back its bank lenders, removing a big area of concern for investors ever since the drugmaker became embroiled in an accounting scandal last year. Valeant has told investors it would work to reduce its debt load, but the company was expected to do so through a series of smaller steps. It would also likely allow Valeant's new chief executive, Joseph Papa, to focus on rebuilding Valeant's core franchises in skin and eye drugs, which have been struggling. If it sells Salix, Valeant's top-selling products would be an off-patent antidepressant named Wellbutrin and Bausch & Lomb's SofLens daily disposable contact lenses. The company would be expected to double down on its skin and eye drugs, such as some acne treatments and over-the-counter vitamins taken for eye health. Valeant also has high hopes for a psoriasis treatment, brodalumab, that is up for regulatory approval. Salix makes treatments for stomach disorders like traveler's diarrhea and irritable bowel syndrome, or IBS. For Takeda, the purchase would come after it lost out on earlier attempts to buy Salix and deliver big-selling gastrointestinal drugs it has been seeking to bolster its lineup of stomach remedies. At the time of Valeant's Salix deal, the Canadian drug company was riding high on a strategy of acquiring companies and consolidating their research-and-development budgets. But then Valeant's business tactics and accounting came under intense scrutiny, leading to government investigations and the departure of its CEO, Michael Pearson, and other executives. Valeant's highflying stock plunged on fears it wouldn't be able to keep up its prior pace of acquisition-led growth and that its $30 billion of debt was too much. Investors have been particularly focused on the roughly $12 billion Valeant owes banks, given that the vast majority of its $19 billion in public bonds don't start coming due before 2020. Valeant took on roughly half its current debt load to pay for Salix after it won a heated bidding war for the company. Valeant -- with a market value of about $8.3 billion at Tuesday's close, after its stock had dropped more than 90% from its highs in 2015 -- has been working with a number of banks to explore sales of various assets, and these efforts are also progressing, the people said. Valeant preferred to sell other parts of its business, but Salix was viewed as the most attractive asset for rivals, they said. Selling Salix for less than it paid in April 2015 could hand Valeant a loss it could use to offset gains from other asset sales. Takeda swooped in with an offer to start the talks. Takeda, Japan's largest drugmaker by revenue, vied for Salix in the previous auction, and combined on an abortive offer for all of Valeant with private-equity TPG, The Wall Street Journal r eported earlier this year. Salix would give Takeda a drug for IBS called Xifaxan that Valeant had predicted could have $1 billion in sales this year. Sales haven't done as well as some analysts expected, however. Many Salix sales representatives left the company, and Xifaxan has faced fierce competition from a competing drug, Viberzi, from Allergan PLC. Meanwhile, Teva Pharmaceutical Industries Ltd. also is working on a generic version of Xifaxan. Takeda is likely betting that its sales force, which already sells products like a fast-growing ulcerative-colitis drug called Entyvio, could help increase sales of Xifaxan and other Salix products. Like other Japanese drug companies, Takeda is seeking growth in the U.S. and other lucrative markets to offset pressures in its home country. The Japanese company has singled out stomach treatments as a priority. In March, its U.S. unit said it was reorganizing to focus on gastrointestinal disorders, along with a few other conditions. --Dana Mattioli contributed to this article. Write to David Benoit at david.benoit@wsj.com and Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com
Ben overigens nieuwsschierig waar het dieptepunt ligt. In eerste instantie dacht ik zo rond de 9 euro. Nu we daar doorheen zijn gezakt houd ik er zelfs rekening mee dat dat ook de oude bodem van rond de 8 kan zijn. Wel valt het me op dat de koopdruk iets aan het toenemen is, waardoor ik de verwachting heb dat we tegen een nieuwe bodem aan het aanhikken zijn. Maar tja de beurs doet toch wat ie wilt en maar rustig afwachten dus. Groet PM
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)